Home
About
Product
News
Honor
Contact
Purchasing
Company News
Industry trends
Purchasing information
2017-07-21
Today, the company announced that it signed the Third Amendment with the existing shareholders and related parties of India Gland, adjusting the transaction to: the company invested no more than US $1091.3 million to acquire about 74% of Gland's equity, including the contingent consideration paid for the listing and sale of Gland Enoxaparin in the United States, which did not exceed US $25 million. The termination date of this transaction is extended to October 3, 2017.
2017-09-20
Congratulations on the establishment of our website
2017-07-18
Panoramic Analysis of China's Foreign Trade in Medical Devices in 2015
Do you know that some medicines need to be protected from light? If you don't know, just take a look
Aprotinin returns to the market or endangers public life
The 17th World Pharmaceutical Raw Materials China Exhibition
Fosun Pharmaceuticals acquired 74% equity of Gland74 to build an international platform for preparations